Comment on editorial 'Pathogenic effector functions of ACPA: where do we stand?'

The recently published paper by Ge *et al*¹ has led to both retractions² and correction notes of papers^{3,4} that have so far been a basis of the current understanding of anti-citrullinated protein antibodies (ACPAs). The recent and well-written editorial by Toes and Pisetsky⁵ confirms the importance of this twist.

However, there is one statement in the editorial that needs to be clarified: 'Notably, the authors who described the monoclonal ACPA with osteoclastogenic and pain-inducing potential notified the community that, in reassessing the original data, the antibodies in question showed 'no measurable affinity for the tested citrullinated peptides' as detailed in a recent correction and retraction note; in other words, the monoclonal antibodies studied were not ACPA. This observation is in line with crystallographic studies of some of these monoclonal antibodies that could not confirm the binding of citrullinated peptides'. The crystal structures and the discovery that the monoclonal antibodies D10 and B02 did not have any citrulline specificity were already made in 2013, just after the now retracted Amara *et al*² paper was published, and this information was at this time communicated to the authors both through discussions and through written notice. To our disappointment, they decided not to retract the paper. Instead, they used these antibodies to prove functions of ACPAs in new papers.

This was also the reason that, several years later, we decided to include the old data of the B02 and D10 antibodies in our paper, showing for the first time the structural interactions between ACPA and citrullinated peptides.¹ It was only after this paper was made public, in August 2018, that the Amara *et al* paper was finally retracted.

It should also be noted that two papers based on these two previous 'ACPA' monoclonal B02 and D10 antibodies have been corrected, stating that it is not possible to conclude on the given data that ACPA specifically induces bone erosions. However, the authors continue to refer to these papers, iterating this statement as a proof. It is obviously critical for the future of rheumatology that published data are correct, and if this turns out not to be the case, it should be corrected as soon as proper information is available.

Rikard Holmdahl

Department of Medical Biochemistry and Biophysics, Section of Medical Inflammation Research, Karolinska Institute, Stockholm, Sweden

Correspondence to Professor Rikard Holmdahl, Department of Medical Inflammation Research, Karolinska Institute, Stockholm 171 77, Sweden; rikard.holmdahl@ki.se

Handling editor Josef S Smolen

Contributors I am the sole author writing this communication.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Holmdahl R. *Ann Rheum Dis* 2020;**79**:e126.

Received 7 June 2019

Accepted 9 June 2019

Published Online First 21 June 2019

► <http://dx.doi.org/10.1136/annrheumdis-2019-215870>

Ann Rheum Dis 2020;**79**:e126. doi:10.1136/annrheumdis-2019-215870

ORCID iD

Rikard Holmdahl <http://orcid.org/0000-0002-4969-2576>

REFERENCES

- Ge C, Xu B, Liang B, *et al*. Structural basis of cross-reactivity of Anti-Citrullinated protein antibodies. *Arthritis Rheumatol* 2019;71:210–21.
- Amara K, Steen J, Murray F, *et al*. Retraction: monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. *J Exp Med* 2019;216.
- Wigerblad G, Bas DB, Fernandes-Cerqueira C, *et al*. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. *Ann Rheum Dis* 2016;75:730–8.
- Krishnamurthy A, Joshua V, Haj Hensvold A, *et al*. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. *Ann Rheum Dis* 2016;75:721–9.
- Toes R, Pisetsky DS. Pathogenic effector functions of ACPA: where do we stand? *Ann Rheum Dis* 2020;**79**:e127.